Effectiveness and tolerability in people with narcolepsy transitioning from sodium oxybate to low-sodium oxybate: Data from the real-world TENOR study

被引:8
作者
Bae, Charles J. [1 ]
Zee, Phyllis C. [2 ]
Leary, Eileen B. [3 ]
Fuller, Douglas S. [4 ]
Macfadden, Wayne [4 ,6 ]
Candler, Shawn [4 ]
Steininger, Teresa L. [3 ]
Husain, Aatif M. [5 ]
机构
[1] Univ Penn, Penn Med, Philadelphia, PA USA
[2] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
[3] Jazz Pharmaceut, Palo Alto, CA USA
[4] Jazz Pharmaceut, Philadelphia, PA USA
[5] Duke Univ, Med Ctr, Durham, NC USA
[6] 2005 Market St, Philadelphia, PA 19103 USA
关键词
Narcolepsy; Excessive daytime sleepiness; Epworth Sleepiness Scale; Cataplexy; Sodium oxybate; Low -sodium oxybate; BLOOD-PRESSURE; WITHDRAWAL; BURDEN;
D O I
10.1016/j.sleep.2023.05.023
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives: The Transition Experience of persons with Narcolepsy taking Oxybate in the Real-world (TENOR) study was conducted to provide real-world insight into the experience of people with narcolepsy switching from sodium oxybate (SXB) to low-sodium oxybate (LXB; 92% less sodium than SXB). Methods: TENOR is a patient-centric, prospective, observational, virtual-format study. Participants were adults with narcolepsy (type 1 or 2) who were transitioning from SXB to LXB treatment (& PLUSMN;7 days from LXB initiation). Effectiveness and tolerability data were collected online from baseline (taking SXB) through 21 weeks (taking LXB) via daily and weekly diaries and questionnaires, including the Epworth Sleepiness Scale (ESS), the Functional Outcomes of Sleep Questionnaire, short version (FOSQ-10), and the British Columbia Cognitive Complaints Inventory (BC-CCI). Results: TENOR participants (N = 85) were 73% female with a mean (SD) age of 40.3 (13.0) years. Mean (SD) ESS scores decreased numerically throughout the transition from SXB to LXB (baseline: 9.9 [5.2]; week 21: 7.5 [4.7]), with 59.5% and 75.0% of participants having scores in the normal range (& LE;10) at baseline and week 21, respectively. Mean (SD) FOSQ-10 scores (baseline: 14.4 [3.4]; week 21: 15.2 [3.2]) and BC-CCI scores (baseline: 6.1 [4.4]; week 21: 5.0 [4.3]) also remained stable. The most common symptoms related to tolerability reported by participants at baseline were sleep inertia, hyperhidrosis, and dizziness (45.2%, 40.5%, and 27.4%, respectively), which decreased in prevalence by week 21 (33.8%, 13.2%, and 8.8%, respectively). Conclusions: Findings from TENOR confirm maintenance of effectiveness and tolerability when transitioning from SXB to LXB treatment. & COPY; 2023 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
引用
收藏
页码:65 / 74
页数:10
相关论文
共 41 条
[11]   Development of the FOSQ-10: A Short Version of the Functional Outcomes of Sleep Questionnaire [J].
Chasens, Eileen R. ;
Ratcliffe, Sarah J. ;
Weaver, Terri E. .
SLEEP, 2009, 32 (07) :915-919
[12]   Pharmacokinetics, bioavailability, and bioequivalence of lower-sodium oxybate in healthy participants in two open-label, randomized, crossover studies [J].
Chen, Cuiping ;
Jenkins, Jack ;
Zomorodi, Katie ;
Skowronski, Roman .
CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 14 (06) :2278-2287
[13]   Cytochrome P450 2D6 genotype affects the pharmacokinetics of controlled-release paroxetine in healthy Chinese subjects: comparison of traditional phenotype and activity score systems [J].
Chen, Rui ;
Wang, Haotian ;
Shi, Jun ;
Shen, Kai ;
Hu, Pei .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 71 (07) :835-841
[14]   Comorbidities in a community sample of narcolepsy [J].
Cohen, Alexander ;
Mandrekar, Jay ;
St Louis, Erik K. ;
Silber, Michael H. ;
Kotagal, Suresh .
SLEEP MEDICINE, 2018, 43 :14-18
[15]   Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP) [J].
Cook, Nancy R. ;
Cutler, Jeffrey A. ;
Obarzanek, Eva ;
Buring, Julie E. ;
Rexrode, Kathryn M. ;
Kumanyika, Shiriki K. ;
Appel, Lawrence J. ;
Whelton, Paul K. .
BMJ-BRITISH MEDICAL JOURNAL, 2007, 334 (7599) :885-888B
[16]   Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications [J].
Dauvilliers, Yves ;
Sonka, Karel ;
Bogan, Richard K. ;
Partinen, Markku ;
Del Rio Villegas, Rafael ;
Foldvary-Schaefer, Nancy ;
Skowronski, Roman ;
Chen, Abby ;
Black, Jed ;
Skobieranda, Franck ;
Thorpy, Michael J. .
CNS DRUGS, 2022, 36 (06) :633-647
[17]   Does AHI Value Enough for Evaluating the Obstructive Sleep Apnea Severity? [J].
Dündar Y. ;
Saylam G. ;
Tatar E.Ç. ;
Özdek A. ;
Korkmaz H. ;
Fırat H. ;
Ardıç S. .
Indian Journal of Otolaryngology and Head & Neck Surgery, 2015, 67 (Suppl 1) :16-20
[18]   Weight loss in narcolepsy patients treated with sodium oxybate [J].
Husain, Aatif M. ;
Ristanovic, Ruzica K. ;
Bogan, Richard K. .
SLEEP MEDICINE, 2009, 10 (06) :661-663
[19]  
Iverson GL, 2013, ANN CLIN PSYCHIATRY, V25, P135
[20]   A NEW METHOD FOR MEASURING DAYTIME SLEEPINESS - THE EPWORTH SLEEPINESS SCALE [J].
JOHNS, MW .
SLEEP, 1991, 14 (06) :540-545